Jan 11 (Reuters) - Puma Biotechnology Inc:
* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY
* PUMA BIOTECHNOLOGY SAYS IT INTENDS TO MODIFY SUMMARY OF PRODUCT CHARACTERISTICS IN ITS MARKETING AUTHORIZATION APPLICATION FOR NERATINIB
* PUMA BIOTECHNOLOGY SAYS TO MODIFY SUMMARY FOR NERATINIB TO FURTHER REFINE INTENDED POPULATION TO PATIENTS AT A HIGH RISK OF DISEASE RECURRENCE Source text: ( bit.ly/2D21ru9 ) Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.